Cyclacel(CYCC)

Search documents
Cyclacel(CYCC) - 2019 Q2 - Earnings Call Transcript
2019-08-14 02:56
Cyclacel Pharmaceuticals, Inc. (NASDAQ:CYCC) Q2 2019 Results Earnings Conference Call August 13, 2019 4:30 PM ET Company Participants Paul McBarron - Executive VP of Finance, CFO, COO, Secretary & Executive Director Spiro Rombotis - President, CEO & Executive Director Alexander Fudukidis - IR, Russo Partners LLC Conference Call Participants Operator Good afternoon, and welcome to the Cyclacel Pharmaceuticals Second Quarter 2019 Results Conference Call and Webcast. (Operator Instructions) The company will al ...
Cyclacel(CYCC) - 2019 Q2 - Quarterly Report
2019-08-13 21:11
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2019 OR ¨ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from __________________ to __________________ Commission file number 000-50626 CYCLACEL PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) ...
Cyclacel(CYCC) - 2019 Q1 - Earnings Call Transcript
2019-05-14 23:21
Start Time: 16:30 January 1, 0000 4:50 PM ET Cyclacel Pharmaceuticals, Inc. (NASDAQ:CYCC) Q1 2019 Earnings Conference Call May 14, 2019, 16:30 PM ET Company Participants Spiro Rombotis - President and CEO Paul McBarron - EVP, Finance and COO and Secretary Judy Chiao - VP, Clinical Development and Regulatory Affairs Alexander Fudukidis - IR, Russo Partners LLC Conference Call Participants Wangzhi Li - Ladenburg Thalmann & Co. Operator Good afternoon, and welcome to the Cyclacel Pharmaceuticals First Quarter ...
Cyclacel(CYCC) - 2019 Q1 - Quarterly Report
2019-05-14 21:17
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2019 OR ¨ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ______ to ______ Commission file number 000-50626 | --- | --- | |--------------------------------------------------------------------------------------------- ...
Cyclacel(CYCC) - 2018 Q4 - Annual Report
2019-03-28 20:28
TABLE OF CONTENTS UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2018 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission file number 00-50626 CYCLACEL PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 91-1707622 (State or Other Jurisdiction of Incorp ...